Theorem Clinical Research

Global News

Report: Gaps exist between research volunteers and Parkinson's clinical studies

Monday, February 23, 2015 01:03 PM

De-identified data in Fox Trial Finder could illuminate trends about how Parkinson's family history or connection, length of time since diagnosis, previous medical procedures and simple geography affect recruitment, helping studies connect with eligible volunteers and vice versa.

More... »

Quest Diagnostics

TransCelerate selects DrugDev to develop and host the Investigator Registry

Monday, February 23, 2015 01:03 PM

DrugDev has been selected by TransCelerate BioPharma, a nonprofit organization with membership comprised of 20+ biopharmaceutical companies, to develop and host its Investigator Registry.

More... »


Bristol-Myers Squibb to acquire Flexus Biosciences

Monday, February 23, 2015 01:02 PM

Bristol-Myers Squibb has signed a definitive agreement to acquire all of the outstanding capital stock of Flexus Biosciences, a San Carlos, Calif.-based, privately held biotech focused on the discovery and development of novel anti-cancer therapeutics. The transaction has a potential total consideration of $1.25 billion, including $800 million upfront and development milestones that, upon achievement, could total up to $450 million. The transaction has been approved by the boards of directors of both companies and by the stockholders of Flexus.

More... »

Rigel, Bristol-Myers Squibb ink R&D collaboration

Monday, February 23, 2015 01:01 PM

Rigel Pharmaceuticals and Bristol-Myers Squibb have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel’s extensive portfolio of small molecule TGF beta receptor kinase inhibitors. T

More... »

LabCorp completes acquisition of Covance

Monday, February 23, 2015 01:00 PM

Laboratory Corporation of America Holdings (LabCorp) has completed its acquisition of Covance, following its definitive purchase agreement Nov. 2, 2014.

More... »

Patient Recruitment for Special Populations

Monday, February 23, 2015 08:00 AM

Patient recruitment for clinical trials is one of the most important, yet underfunded, components of a clinical trial.

More... »

Merck Serono, Sysmex Inostics open liquid biopsy RAS biomarker testing center

Friday, February 20, 2015 12:32 PM

Merck Serono, the biopharmaceutical business of Merck, has announced the opening of the first liquid biopsy RAS biomarker testing center in Vall d'Hebron's Institute of Oncology, Barcelona, Spain, and initially will test patients as part of its research program. This is an important milestone in making the new liquid biopsy RAS test available to patients with metastatic colorectal cancer (mCRC), and a significant step forward in Merck Serono's collaboration with Sysmex Inostics, a Germany-based molecular diagnostic company.

More... »

WHO urges governments to invest $34B for neglected tropical diseases

Friday, February 20, 2015 12:20 PM

The World Health Organization (WHO) has released a report urging countries to scale up their investment in tackling 17 neglected tropical diseases in order to improve the health and well-being of more than 1.5 billion people. This investment would represent as little as 0.1% of current domestic expenditure on health in affected low- and middle-income countries for the period 2015-2030.

More... »

NIH expands tuberculosis research program, awards $105.3M

Thursday, February 19, 2015 02:40 PM

The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, is expanding its Tuberculosis Research Units (TBRU) program in an effort to drive innovation in tuberculosis (TB) research. NIAID is awarding up to $15.2 million in fiscal year 2015 and as much as $105.3 million over seven years to fund four institutions that will act as a collaborative TBRU network.

More... »

Actavis intends to adopt Allergan following acquisition

Thursday, February 19, 2015 02:39 PM

Actavis, headquartered in Dublin, Ireland, will adopt a new corporate name—Allergan—following the anticipated successful completion of the acquisition of Allergan. The company said that it intends to use the Allergan name as its corporate name and for its global branded pharmaceutical portfolio, and will retain the Actavis name for select geographic regions and product portfolios. The change in corporate name would be subject to approval by Actavis' shareholders at its annual general meeting later this year. 

More... »

`

CWWeekly

March 23

Industry welcomes FDA draft guidance outlining the use of electronic Informed Consent for trials

Apple launches ResearchKit platform to tap millions of iPhone users to enroll in observational studies using apps

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs